Bone Marrow Transplantation News

SAN DIEGO — CPX-351 conferred better outcomes after allogeneic hematopoietic stem cell transplantation than standard cytarabine and daunorubicin in older patients with high-risk acute myeloid leukemia, according to results of an exploratory analysis of a phase 3 trial presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — The HemOnc Today and Healio.com/HemOnc team will present comprehensive live coverage from the ASH Annual Meeting and Exposition beginning Dec. 3.

A publication in Journal of Clinical Oncology reports the results of a randomized trial that compared rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, or R-CHOP, to high-dose sequential chemotherapy with autologous stem cell transplantation as first-line therapy in patients with poor-risk diffuse large B-cell lymphoma.

Inpatient palliative care improved quality of life among hematopoietic stem cell transplant recipients, according to a nonblinded randomized clinical trial published in JAMA.

Approximately 14,000 patients in the United States could benefit from a bone marrow transplant each year; however, only four out of every 10 will receive one, according to data from the DKMS organization.

Patients who underwent hematopoietic stem cell transplantation had a significantly increased rate of vitiligo development compared with controls, according to study results published in the Journal of the American Academy of Dermatology.

The launch of the Watson for Genomics sequencing service has the potential to bring precision medicine to cancer treatment centers worldwide, according to a press release issued by IBM Watson Health and Quest Diagnostics.

Patients with advanced cancer should receive dedicated, early palliative care concurrently with standard oncology treatment, according to ASCO’s updated guidelines published in Journal of Clinical Oncology.

Bruce Clurman, MD, has been appointed executive vice president and deputy director of Fred Hutchinson Cancer Research Center.

Patients with cancer may have an increased risk for treatment-related and -unrelated injuries in the periods preceding and following their cancer diagnosis, according to the results of a registry study conducted in Sweden.